This study aimed to explore biomarkers in Huntington’s disease (HD) using various multi-omics platforms to profile a selection of both clinical and preclinical samples. By employing both targeted and untargeted approaches in proteomics, lipidomics, and metabolomics, we sought to identify molecular signatures that could enhance understanding of disease progression and inform the development of targeted treatments.
Poster
View the poster here:
PACE (Pathways to Antimicrobial Clinical Efficacy) and the UK Health Security Agency (UKHSA) have released five new contemporary antimicrobial resistance (AMR) strain panels, giving innovators worldwide a resource to test novel therapeutics and diagnostics against today’s resistance patterns.
New appointments support MDC’s mission to turn drug discovery into commercial breakthroughs.
